Ivonescimab for the Treatment of Thymic Cancer
Ivonescimab for the Treatment of Thymic Cancer
Recruiting · NCT06980077 · Registry updated 2026-10-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ivonescimab for the Treatment of Thymic Cancer | thymic carcinoma | Recruiting | Phase 2 | 2026-10-05 | NCT06980077 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jonsson Comprehensive Cancer Center | 115 |
| Summit Therapeutics | 31 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 133 |
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | United States | 126 |
| University of California at Davis (UCD) | Davis | United States | 1 |
| University of California at Irvine (UCI) | Irvine | United States | 1 |
| University of California at San Francisco (UCSF) | San Francisco | United States | 1 |